Authors : Xin Cui, Yueming Zhu, Lidan Zeng, Mengyuan Zhang, Amad Uddin, Theresa W Gillespie, Lauren E McCullough, Shaying Zhao, Mylin A Torres, Yong Wan Source : This study elucidates a molecular mechanism by which Retatrutide overcomes therapeutic resistance in obese triple-negative breast cancer (TNBC)
This enhanced potency sometimes allows reaching target outcomes at lower total doses with tirzepatide versus semaglutide monotherapy
Step 1: Download and fill out the application form Interested patients should download the PAP Application Form or request a copy from their healthcare provider
However, new research suggests a link between weight loss drugs and blindness (and other eye issues), leading some to refer to the issue as Ozempic blindness. A small study published in JAMA Ophthalmology analyzed data from nine patients who developed severe vision issues, including sudden blindness, while taking semaglutide (Wegovy, Ozempic) or tirzepatide (Mounjaro, Zepbound)
